The global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market is witnessing remarkable growth as pharmaceutical and biotechnology companies increasingly outsource drug development and manufacturing activities to specialized service providers. According to the latest industry analysis, the global pharmaceutical CDMO market size was valued at USD 200.9 billion in 2024 and is projected to grow from USD 214.69 billion in 2025 to USD 378.94 billion by 2033, registering a CAGR of 6.8% during the forecast period (2025–2033).
The growing complexity of drug development, rising investments in biopharmaceutical research, and the increasing demand for cost-efficient manufacturing solutions are driving the expansion of the pharmaceutical CDMO industry globally. Pharmaceutical companies are focusing on outsourcing development and manufacturing operations to CDMOs to improve operational efficiency, reduce infrastructure costs, and accelerate product commercialization timelines.
Rising Drug Development Complexity Accelerates Market Growth
The pharmaceutical industry is experiencing a major transformation as advanced therapies, biologics, and personalized medicines become increasingly common. Drug development costs continue to rise significantly, encouraging pharmaceutical companies to collaborate with CDMOs that possess specialized expertise and advanced manufacturing infrastructure.
The World Health Organization estimated that developing a new drug can cost anywhere between USD 43.4 million and USD 4.2 billion. As a result, outsourcing to CDMOs has become a strategic necessity for pharmaceutical companies looking to minimize financial risk while accessing advanced technologies and regulatory expertise.
Moreover, the increasing number of clinical trials worldwide is further boosting demand for CDMO services. According to ClinicalTrials.gov, approximately 477,237 clinical studies were registered globally in 2023, reflecting the strong momentum in pharmaceutical research activities.
Growing Demand for Biopharmaceuticals and Rare Disease Therapies
One of the key trends shaping the pharmaceutical CDMO market is the increasing demand for biopharmaceuticals aimed at treating rare and chronic diseases. CDMOs are expanding their biologics manufacturing capabilities to meet growing industry requirements.
In January 2024, EXO Biologics SA launched ExoXpert, a dedicated CDMO platform for GMP production of exosomes used in rare disease treatment. This development highlights the growing focus on advanced therapeutic manufacturing and specialized biologics production.
Additionally, sustainability is becoming a major priority across the pharmaceutical industry. CDMOs are increasingly implementing green chemistry and environmentally friendly manufacturing practices to reduce operational emissions and improve energy efficiency. In May 2024, WuXi AppTec announced that its Singapore facility would adopt industry-leading green chemistry technologies as part of its sustainability initiatives.
North America Leads While Asia-Pacific Emerges as Fastest Growing Region
North America dominated the pharmaceutical CDMO market in 2024, accounting for the largest market share due to strong pharmaceutical R&D investments, advanced healthcare infrastructure, and the presence of major pharmaceutical manufacturers.
The U.S. market remains a major contributor to regional growth, supported by increasing outsourcing activities and rising demand for innovative therapies. The U.S. FDA reported 98 medicine shortages in 2023, further encouraging pharmaceutical firms to partner with CDMOs for reliable manufacturing support.
Meanwhile, Asia-Pacific is expected to witness the fastest growth during the forecast period. Countries such as India and China are emerging as attractive outsourcing destinations due to lower manufacturing costs, expanding pharmaceutical industries, and government support for biotechnology development.
India continues to strengthen its position as a global CDMO hub by offering manufacturing costs nearly 50% lower than the U.S. and maintaining one of the largest networks of FDA-approved manufacturing facilities outside the United States.
Pharmaceutical Manufacturing Services Segment Holds Largest Market Share
Based on service type, the pharmaceutical manufacturing services segment dominates the market due to the rising demand for Active Pharmaceutical Ingredients (APIs) and Final Dosage Forms (FDFs). The growth of specialty pharmaceuticals and complex formulations is further driving segment expansion.
The Phase III research segment also accounts for a significant share of the market as pharmaceutical companies increasingly outsource large-scale clinical trial manufacturing and regulatory support services.
Large pharmaceutical companies remain the dominant end-users in the market, relying heavily on CDMOs to streamline operations, improve scalability, and accelerate product launches.
Key Players Driving Competition in the Pharmaceutical CDMO Market
Leading companies operating in the global pharmaceutical CDMO market are focusing on expanding manufacturing capacities, strengthening biologics capabilities, and adopting advanced technologies to maintain competitive advantages.
Key Players in the Pharmaceutical CDMO Market
- Thermo Fisher Scientific, Inc.
- Lonza Group
- WuXi Apptec
- WuXi Biologics
- AbbVie, Inc.
- Catalent, Inc.
- Samsung Biologics
- Evonik Industries AG
- FUJIFILM Holding Corporation
- Siegfried Holding AG
- Boehringer Ingelheim International
- Merck KGaA
- Almac Group
- Charles River Laboratories
- Asymchem Inc.
Recent industry developments continue to strengthen market growth. In February 2024, Catalent Inc. announced a USD 16.5 billion acquisition agreement with Novo Holdings. Additionally, Recipharm entered into a strategic collaboration with Medspray and Resyca for the development of soft mist nasal delivery devices.
Gain access to expanded insights on competitive strategies, market size, and regional analysis. View our Market Report Overview here:Â https://straitsresearch.com/report/pharmaceutical-contract-development-and-manufacturing-organization-market
About Straits Research
Straits Research is a leading provider of business intelligence, specializing in research, analytics, and advisory services. The company delivers in-depth market reports and strategic insights across diverse industries including healthcare, pharmaceuticals, chemicals, technology, automotive, aerospace, energy, and consumer goods. With a strong focus on data accuracy and actionable intelligence, Straits Research supports organizations in making informed business decisions and identifying growth opportunities in competitive global markets.
